scholarly journals Real-World Treatment Patterns and Outcomes from an Electronic Medical Records Database for Patients with Rheumatoid Arthritis Treated with Repository Corticotropin Injection

2021 ◽  
Vol Volume 13 ◽  
pp. 315-323
Author(s):  
Kyle Hayes ◽  
Mary P Panaccio ◽  
Parul Houston ◽  
John Niewoehner ◽  
Mohammed Fahim ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Electronic Medical Records ◽  
Real World ◽  
Medical Records ◽  
Treatment Patterns

scholarly journals Descriptive epidemiology of hip and knee replacement in rheumatoid arthritis: An analysis of UK electronic medical records

2020 ◽  
Vol 50 (2) ◽  
pp. 237-244 ◽  
Author(s):  
Samuel Hawley ◽  
Christopher J. Edwards ◽  
Nigel K. Arden ◽  
Antonella Delmestri ◽  
Cyrus Cooper ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Electronic Medical Records ◽  
Knee Replacement ◽  
Medical Records ◽  
Descriptive Epidemiology

scholarly journals Treatment patterns and clinical outcomes with palbociclib-based therapy received in US community oncology practices

2020 ◽  
Author(s):  
Junji Lin ◽  
Lynn McRoy ◽  
Maxine D Fisher ◽  
Nan Hu ◽  
Cralen Davis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Outcomes ◽  
Real World ◽  
Medical Records ◽  
Metastatic Breast ◽  
Patient Characteristics ◽  
Treatment Patterns ◽  
Community Oncology ◽  
Label Indication ◽  
Free Rate

Background: Limited studies have evaluated palbociclib-based therapy use in patients with advanced/metastatic breast cancer in the real world. This retrospective study used medical records from US community oncology practices to address the gap. Materials & methods: Eligible patients receiving palbociclib-based therapy per label indication from 3 February 2015 to 31 December 2017 were included. Descriptive analyses were conducted for patient characteristics, treatment patterns and clinical outcomes. Results: The study included 233 patients who received palbociclib + aromatase inhibitor (P+AI) and 48 who received palbociclib + fulvestrant (P+F). Real-world progression-free rate for P+AI was 69.8% (46.8%) at 12 (24) months (P+F: 43.5% [39.9%]) months. Real-world survival rate was 89.8% (71.4%) at 12 (24) months (P+F: 76.3% [65.0%]). Conclusion: The study findings are consistent with previous studies of palbociclib-based therapy.

Sign in / Sign up

Export Citation Format

Share Document